Guanfacine for Hyperactivity in Children With Down Syndrome (HYPEbeGONE_DS)
Stopped early · Phase 2 · Has a placebo group
Conditions studied: Hyperactivity in Children With Down Syndrome, Impulsivity in Children With Down Syndrome
In brief
The primary purpose of this study is to determine efficacy of guanfacine immediate release (GIR) for the treatment of hyperactivity/impulsivity and inattention in children 6-12 years of age with Down syndrome (DS) after 8 weeks of treatment.
Key facts
- Study ID
- NCT06042257
- Run by
- Rachel G. Greenberg, MD, MB, MHS
- People needed
- 3
- Starts
- 2024-12-09
- Expected to finish
- 2025-08-12
- Last updated by the study team
- 2026-04-17
Who can join
Age: 6 and older, up to 12. Sex: any. Healthy volunteers: accepted.
Where it is running
- Phoenix Childrens Hospital — Phoenix, Arizona, United States
- Emory University — Atlanta, Georgia, United States
- Ann and Robert H. Lurie Hospital of Chicago — Chicago, Illinois, United States
- University of Iowa — Iowa City, Iowa, United States
- Kennedy Krieger Institute — Baltimore, Maryland, United States
- Boston Children's Hospital — Boston, Massachusetts, United States
- Massachusetts General Hospital — Lexington, Massachusetts, United States
- Atrium Health-Wake Forest School of Medicine — Charlotte, North Carolina, United States
- Duke University Hospital — Durham, North Carolina, United States
- Akron Children's Hospital — Akron, Ohio, United States
- Cincinnati Children's Hospital — Cincinnati, Ohio, United States
- Virginia Center for Children — Richmond, Virginia, United States
- University of Washington — Seattle, Washington, United States
- University of Wisconsin Madison — Madison, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.